Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

129 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor.
Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CDM, Silberman S, Dimitrijevic S, Fletcher JA. Heinrich MC, et al. Among authors: van den abbeele ad. J Clin Oncol. 2023 Nov 1;41(31):4829-4836. doi: 10.1200/JCO.22.02771. J Clin Oncol. 2023. PMID: 37890277 Clinical Trial.
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H. Demetri GD, et al. Among authors: van den abbeele ad. N Engl J Med. 2002 Aug 15;347(7):472-80. doi: 10.1056/NEJMoa020461. N Engl J Med. 2002. PMID: 12181401 Free article. Clinical Trial.
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.
Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CD, Silberman S, Dimitrijevic S, Fletcher JA. Heinrich MC, et al. Among authors: van den abbeele ad. J Clin Oncol. 2003 Dec 1;21(23):4342-9. doi: 10.1200/JCO.2003.04.190. J Clin Oncol. 2003. PMID: 14645423 Clinical Trial.
Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors.
Desai J, Shankar S, Heinrich MC, Fletcher JA, Fletcher CD, Manola J, Morgan JA, Corless CL, George S, Tuncali K, Silverman SG, Van den Abbeele AD, van Sonnenberg E, Demetri GD. Desai J, et al. Among authors: van sonnenberg e, van den abbeele ad. Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5398-405. doi: 10.1158/1078-0432.CCR-06-0858. Clin Cancer Res. 2007. PMID: 17875769
Major response to imatinib mesylate in KIT-mutated melanoma.
Hodi FS, Friedlander P, Corless CL, Heinrich MC, Mac Rae S, Kruse A, Jagannathan J, Van den Abbeele AD, Velazquez EF, Demetri GD, Fisher DE. Hodi FS, et al. Among authors: van den abbeele ad. J Clin Oncol. 2008 Apr 20;26(12):2046-51. doi: 10.1200/JCO.2007.14.0707. J Clin Oncol. 2008. PMID: 18421059 No abstract available.
Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure.
Demetri GD, Heinrich MC, Fletcher JA, Fletcher CD, Van den Abbeele AD, Corless CL, Antonescu CR, George S, Morgan JA, Chen MH, Bello CL, Huang X, Cohen DP, Baum CM, Maki RG. Demetri GD, et al. Among authors: van den abbeele ad. Clin Cancer Res. 2009 Sep 15;15(18):5902-9. doi: 10.1158/1078-0432.CCR-09-0482. Epub 2009 Sep 8. Clin Cancer Res. 2009. PMID: 19737946 Free PMC article. Clinical Trial.
Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial.
George S, Wang Q, Heinrich MC, Corless CL, Zhu M, Butrynski JE, Morgan JA, Wagner AJ, Choy E, Tap WD, Yap JT, Van den Abbeele AD, Manola JB, Solomon SM, Fletcher JA, von Mehren M, Demetri GD. George S, et al. Among authors: van den abbeele ad. J Clin Oncol. 2012 Jul 1;30(19):2401-7. doi: 10.1200/JCO.2011.39.9394. Epub 2012 May 21. J Clin Oncol. 2012. PMID: 22614970 Free PMC article. Clinical Trial.
Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.
Ben-Ami E, Barysauskas CM, von Mehren M, Heinrich MC, Corless CL, Butrynski JE, Morgan JA, Wagner AJ, Choy E, Yap JT, Van den Abbeele AD, Solomon SM, Fletcher JA, Demetri GD, George S. Ben-Ami E, et al. Among authors: van den abbeele ad. Ann Oncol. 2016 Sep;27(9):1794-9. doi: 10.1093/annonc/mdw228. Epub 2016 Jul 1. Ann Oncol. 2016. PMID: 27371698 Free PMC article. Clinical Trial.
Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas.
Heymach JV, Desai J, Manola J, Davis DW, McConkey DJ, Harmon D, Ryan DP, Goss G, Quigley T, Van den Abbeele AD, Silverman SG, Connors S, Folkman J, Fletcher CD, Demetri GD. Heymach JV, et al. Among authors: van den abbeele ad. Clin Cancer Res. 2004 Sep 1;10(17):5732-40. doi: 10.1158/1078-0432.CCR-04-0157. Clin Cancer Res. 2004. PMID: 15355900 Clinical Trial.
129 results